679 results on '"Ianotto, Jean‐Christophe"'
Search Results
2. Distinct clinico-molecular arterial and venous thrombosis scores for myeloproliferative neoplasms risk stratification
3. Prediction of major bleeding events in 1381 patients with essential thrombocythemia
4. Créer une communauté de chefs de service pour répondre aux défis du système hospitalier : première expérience en hématologie
5. First-line second generation tyrosine kinase inhibitors in patients with newly diagnosed accelerated phase chronic myeloid leukemia
6. Real-world study of children and young adults with myeloproliferative neoplasms: identifying risks and unmet needs
7. Different number of circulating CD34 + cells in essential thrombocythemia, prefibrotic/early primary myelofibrosis, and overt primary myelofibrosis
8. Achievement of rapid complete remission in an 87-year-old female patient with azacytidine-venetoclax for blastic plasmacytoid dendritic cell neoplasm
9. Unmet clinical needs in the management of CALR-mutated essential thrombocythaemia: a consensus-based proposal from the European LeukemiaNet
10. Direct oral anticoagulants for myeloproliferative neoplasms: results from an international study on 442 patients
11. Genomic analysis of primary and secondary myelofibrosis redefines the prognostic impact of ASXL1 mutations: a FIM study
12. Evaluation of beta-2 microglobulin, erythropoietin and tobacco use in polycythemic cases
13. Long-term follow-up of JAK2 exon 12 polycythemia vera: a French Intergroup of Myeloproliferative Neoplasms (FIM) study
14. JAK2 V617F polycythemia vera and essential thrombocythemia: dynamic clinical features associated with long-term outcomes
15. Leukemic evolution of polycythemia vera and essential thrombocythemia: genomic profiles predict time to transformation
16. Evaluation of posaconazole antifungal prophylaxis in reducing the incidence of invasive aspergillosis in patients with acute myeloid leukemia
17. Role of red cell mass evaluation in myeloproliferative neoplasms with splanchnic vein thrombosis and normal hemoglobin value: a study of the France Intergroupe des Syndromes myeloprolifératifs
18. Distinct clinico-molecular arterial and venous thrombosis scores for myeloproliferative neoplasms risk stratification
19. Different impact of calreticulin mutations on human hematopoiesis in myeloproliferative neoplasms
20. Efficacy and tolerability of Janus kinase inhibitors in myelofibrosis: a systematic review and network meta-analysis
21. CALR‐mutated patients with low allele burden represent a specific subtype of essential thrombocythemia: A study on behalf of FIM and GBMHM.
22. Assessment of the lipemia index determined by the Atellica CH 930 analyzer for the detection of monoclonal immunoglobulins
23. Simulated patient and role play methodologies for communication skills and empathy training of undergraduate medical students
24. Symptom burden profile in myelofibrosis patients with thrombocytopenia: Lessons and unmet needs
25. Discontinuation of dasatinib or nilotinib in chronic myeloid leukemia: interim analysis of the STOP 2G-TKI study
26. Assessment of the lipemia index determined by the Atellica CH 930 analyzer for the detection of monoclonal immunoglobulins.
27. Data from Evaluation of Residual Disease and TKI Duration Are Critical Predictive Factors for Molecular Recurrence after Stopping Imatinib First-line in Chronic Phase CML Patients
28. Supplemental Table S2 from Osteogenic Potential of Mesenchymal Stromal Cells Contributes to Primary Myelofibrosis
29. Differences between aquagenic and non‐aquagenic pruritus in myeloproliferative neoplasms: An observational study of 500 patients
30. Presence of atypical thrombopoietin receptor (MPL) mutations in triple-negative essential thrombocythemia patients
31. Clinical and molecular response to interferon-α therapy in essential thrombocythemia patients with CALR mutations
32. Encephalitozoon hellem in a patient with CD4+ T-cell prolymphocytic leukemia: case report and genomic identification
33. Incidence and impact of atrial arrhythmias on thrombotic events in MPNs
34. Administration of direct oral anticoagulants in patients with myeloproliferative neoplasms
35. JAK2V617F and calreticulin mutations in recurrent venous thromboembolism: results from the EDITH prospective cohort
36. Would you like to take some more ruxolitinib after your fedratinib?
37. Coexisting Myeloproliferative and Lymphoproliferative Neoplasms: A European Multicenter Retrospective Study
38. Prospective Follow-up of Patients with Myelofibrosis (MF) and Treated with Ruxolitinib in France: The Rumycup Study
39. Impact of the COVID-19 Epidemic on Patients with Myeloproliferative Neoplasia: The French Prospective Observational Study Covim
40. Final Results of Ruxopeg, a Phase 1/2 Adaptive Randomized Trial of Ruxolitinib (Rux) and Pegylated Interferon Alpha (IFNa) 2a in Patients with Myelofibrosis (MF)
41. Thrombosis with Non-Proliferative Complete Blood Count Indicative of Underlying Myeloproliferative Neoplasm, Sythrom, a Study on Behalf of the FIM Group
42. Actualités
43. ESDR101 - Aquagenic and non-aquagenic pruritus need to be differentiated in MPN: A study of 500 patients
44. Advances in management of primary myelofibrosis and polycythaemia vera: Implications in clinical practice.
45. Benefice and pitfall of direct oral anticoagulants in very high-risk myeloproliferative neoplasms
46. Validation of thrombotic risk factors in 1381 patients with essential thrombocythaemia: A multicentre retrospective real‐life study
47. Histological and genetic characterization and follow-up of 130 patients with chronic triple-negative thrombocytosis
48. Attentes des infirmiers libéraux dans la prise en soins des patients en oncologie et en hématologie
49. Myeloproliferative neoplasms - a global view
50. Second tyrosine kinase inhibitor discontinuation attempt in patients with chronic myeloid leukemia
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.